Key statistics
On Monday, Chromadex Corp (CDXC:NAQ) closed at 3.32, -28.60% below its 52-week high of 4.65, set on Apr 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.39 |
---|---|
High | 3.39 |
Low | 3.26 |
Bid | 3.26 |
Offer | 3.36 |
Previous close | 3.38 |
Average volume | 231.66k |
---|---|
Shares outstanding | 75.93m |
Free float | 48.90m |
P/E (TTM) | -- |
Market cap | 252.10m USD |
EPS (TTM) | -0.018 USD |
Data delayed at least 15 minutes, as of Oct 07 2024 21:00 BST.
More ▼
Press releases
- ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference
- ChromaDex Appoints Ozan Pamir as Chief Financial Officer
- ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen® IV and Injection Offerings to Additional Leading Wellness Clinics
- ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions
- ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024
- ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+
- ChromaDex Corporation Reports Second Quarter 2024 Financial Results
- ChromaDex to Present at Canaccord Genuity’s 44th Annual Growth Conference
- ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
- ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)
More ▼